EGFR and non-small cell lung carcinoma: Apart from stage IIIA, in which approximately three-quarters of patients received platinum doublet adjuvant chemotherapy, the percentages of patients with stage IB or II who received adjuvant chemotherapy were much higher in the control group of ADAURA compared with those with EGFR-positive NSCLC (stage IB: 27.5% vs 4.4%; stage II: 73.3% vs 53.2%).